<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Solifenacin succinate [YM905, (+)-(1S,3'R)-quinuclidin-3'-yl 1-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate] is a novel muscarinic receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the effects of solifenacin and two other muscarinic receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi>, <z:chebi fb="0" ids="9622">tolterodine</z:chebi> and propiverine, on detrusor overactivity in cerebral infarcted rats </plain></SENT>
<SENT sid="2" pm="."><plain>Evaluation was done under conscious conditions using cystometry 1 day after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The cerebral infarcted rats showed decreases in bladder capacity and voided volume and an increase in residual volume, but no change in micturition pressure </plain></SENT>
<SENT sid="4" pm="."><plain>Solifenacin increased bladder capacity and voided volume at doses of 0.03 mg/kg i.v. or more </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="9622">Tolterodine</z:chebi> increased bladder capacity and voided volume at 0.03 and 0.1 mg/kg i.v., while propiverine increased bladder capacity and voided volume at 1 mg/kg i.v. and at 0.3 and 1 mg/kg i.v., respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, none of the three drugs affected residual volume or micturition pressure </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that solifenacin may improve detrusor overactivity without causing <z:hpo ids='HP_0000016'>urinary retention</z:hpo> and may be a promising drug in the treatment of patients with <z:e sem="disease" ids="C0878773" disease_type="Disease or Syndrome" abbrv="">overactive bladder</z:e> syndrome </plain></SENT>
</text></document>